The government's decision to bust the price as well as monopoly of Bayer's anti-cancer drug, through the process of compulsory licensing now opens up the field for the generic industry to follow suit and could well pave the way for the availability of cheaper drugs for lifestyle diseases.  More generic companies could invoke the compulsory licensing clause of the Indian Patents Act, following Monday's decision to allow Natco Pharma to sell...

A report on ‘State of Indian Agriculture 2011-12’, tabled in the Lok Sabha on Tuesday, has called for reforms to ensure that the sector grows in tandem with the overall GDP of the country. The report says that “achieving an 8-9% rate of growth in the overall GDP may not deliver much in terms of poverty reduction unless agricultural growth accelerates”. Admitting that the sector has undergone ‘significant structural changes’ in...

A non-government organisation campaigning for cheaper essential drugs has proposed an alternative pricing model that seeks to fix retail prices at the average price of all brands in a segment.  The proposal of the All India Drug Action Network (AIDAN) is being examined by the department of pharmaceuticals (DoP), an official said. AIDAN says its new pricing mechanism, which excludes brands that account for the top 20% by sales, will make...

The growth rate of petrol consumption is set to fall below 5% in the current fiscal, the first time in five years. Meanwhile, the consumption of diesel continues to grow at 7%, adding to the losses of the oil marketing companies on account of subsidies. In India, diesel is subsidized while petrol is not, and the price difference has led to more buyers opting for vehicles driven by the cheaper fuel. According...

In a landmark decision, India’s intellectual property office on Monday allowed Hyderabad-based Natco Pharma Ltd to make and sell a copycat version of German drug maker Bayer AG’s patented cancer treatment Nexavar. It’s the first time that an Indian company has been granted the so-called compulsory licence to market a generic version of a patented drug. The drug, patented by Bayer in India in 2008, is used in the treatment of...